Skip to main content

Table 2 Changes in the number of pigs developing fever in various treatment groups over time after classical swine fever virus (CSFV) challengea.

From: Porcine circovirus type 2 (PCV2) infection decreases the efficacy of an attenuated classical swine fever virus (CSFV) vaccine

dpi 27 30 33 36 39 42 45
Group 1 0/6b 0/6 1/6 1/6 1/6 0/6 0/6
Group 2 0/6 6/6 3/6 4/6 3/4 0/1 0/0
Group 3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
Group 4 0/3 1/3 2/3 2/3 2/3 1/3 0/0
  1. Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and group 4: CSFV-challenged.
  2. aThe pigs were inoculated with 105.3 TCID50 of PCV2 (group 1 and 2), 1 dose of LPC vaccine (group 1 and 3), and 106.8 TCID50 of wild-type CSFV (ALD) (group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively.
  3. bNumber of animals with fever/number of surviving animals.